⚡

Tirzepatide (Mounjaro / Zepbound)

✍️ Reviewed by nnng.com Editorial Team · April 2026 · Medical disclaimer

Dual GLP-1/GIP agonist — produces the greatest average weight loss of any approved medication.

📍 GLP-1 / Weight Loss ⏱ Once weekly 💉 SubQ (abdomen, thigh, or upper arm) 🔄 Cycle: Ongoing / long-term ⏳ Half-life: ~5 days ❄️ Storage: 28 days refrigerated

📋 What is Tirzepatide?

Tirzepatide is a dual GLP-1/GIP receptor agonist developed by Eli Lilly. The SURMOUNT trials demonstrated average weight loss of 20.9% of body weight — exceeding semaglutide and approaching bariatric surgery outcomes. Approved as Mounjaro (diabetes) and Zepbound (obesity).

Mechanism: Tirzepatide activates both GLP-1 receptors (appetite suppression, slowed gastric emptying, insulin secretion) and GIP receptors (enhanced insulin secretion, fat cell metabolism, potential additive appetite suppression). The dual mechanism produces synergistic weight loss beyond either hormone alone.

✅ Key Benefits

Average 20.9% body weight reduction (SURMOUNT-1)
Up to 22.5% weight loss in highest-dose group
Superior glycemic control vs semaglutide
Improved lipid profiles
Blood pressure reduction
Potentially better GI tolerability than semaglutide

🧬 Tirzepatide Reconstitution Calculator

Vial Size (mg)

BAC Water (mL)

Dose (mcg)

—

IU to draw on 100-unit syringe

— mL

Concentration: —

Open full calculator with Tirzepatide pre-loaded →

⚠️ Research use only. Not medical advice. Consult a licensed healthcare provider before using any peptide.

💉 Dosing Reference Table

Week	Dose	Notes
1–4	2.5 mg/week	Starting dose — always begin here
5–8	5 mg/week	First escalation
9–12	7.5 mg/week	Mid-range therapeutic dose
13–16	10 mg/week	Most patients see strong response here
17–20	12.5 mg/week	Near-maximum dose
21+	15 mg/week	Maximum approved dose
Maintenance	5–15 mg/week	Lowest dose that maintains results

Tirzepatide titration is every 4 weeks — the slowest GLP-1 titration schedule, reflecting its potency. Many clinicians extend each step to 6–8 weeks for better tolerability. Unlike semaglutide's flat titration, many patients find their 'sweet spot' dose between 7.5–12.5 mg and stay there rather than pushing to 15 mg. Same-day weekly injection, rotate sites.

🔀 Common Stacks

+ Semaglutide (switch, not stack)

Patients may switch from sema to tirz for greater efficacy. Not used in combination.

+ BPC-157

Can help manage GI side effects during titration.

❓ Frequently Asked Questions

How does tirzepatide compare to semaglutide for weight loss?

Head-to-head data from the SURMOUNT-5 trial (2024) showed tirzepatide produced ~47% more weight loss than semaglutide at maximum doses (20.2% vs 13.7% body weight). For most patients, tirzepatide produces superior results. Side effect profiles are similar, with some data suggesting tirzepatide may have slightly better GI tolerability.

Do I always need to titrate to 15 mg?

No. Many patients achieve excellent results at 5–10 mg/week and find higher doses produce diminishing returns with more side effects. The goal is the lowest dose that achieves and maintains your target weight. Some patients maintain well at 2.5–5 mg/week after reaching their goal weight.

Is compounded tirzepatide safe?

Compounded versions exist due to FDA shortage status (as of early 2025). Quality varies by compounder. Ensure acetate or free base form (not 'tirzepatide sodium'). FDA shortage status changes — verify before ordering and ensure compounding pharmacy is 503A/503B compliant.

What if I miss a dose?

If fewer than 4 days have passed, take the missed dose ASAP then resume regular schedule. If 4+ days have passed, skip the missed dose and take the next dose on the regular schedule day. Do not double-dose.